Lucence Diagnostics is an international genomic medicine company founded to fulfill its vision of a world without avoidable cancer deaths. The company invents non-invasive blood tests that improve cancer detection and treatment selection. Lucence targets the most common cancers in Asia using its proprietary amplicon-based ultra-deep sequencing technology and AI-driven data analytics platform. Lucence has offices in Singapore, San Francisco, Hong Kong, and Suzhou. Its services to hospitals and doctors are delivered worldwide through an accredited central laboratory. For more information, please visit www.lucencedx.com.